Mayinglong Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Mayinglong Pharmaceutical Group Co Ltd (600993) has an Asset Resilience Ratio of 27.96% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Mayinglong Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Check Mayinglong Pharmaceutical Group Co Ltd (600993) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Mayinglong Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600993 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.58 Billion | 27.96% |
| Total Liquid Assets | CN¥1.58 Billion | 27.96% |
Asset Resilience Insights
- Very High Liquidity: Mayinglong Pharmaceutical Group Co Ltd maintains exceptional liquid asset reserves at 27.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Mayinglong Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Mayinglong Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
JW Pharmaceutical Corp
KO:001067 |
Drug Manufacturers - Specialty & Generic | 8.17% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275 |
Drug Manufacturers - Specialty & Generic | 14.80% |
|
Fuan Pharmaceutical Group Co
SHE:300194 |
Drug Manufacturers - Specialty & Generic | 1.34% |
|
DRI Healthcare Trust
TO:DHT-U |
Drug Manufacturers - Specialty & Generic | 13.91% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 1.03% |
Annual Asset Resilience Ratio for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Mayinglong Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.31% | CN¥506.09 Million ≈ $74.06 Million |
CN¥5.44 Billion ≈ $795.49 Million |
+6.57pp |
| 2024-12-31 | 2.74% | CN¥142.14 Million ≈ $20.80 Million |
CN¥5.18 Billion ≈ $758.28 Million |
+1.43pp |
| 2023-12-31 | 1.31% | CN¥63.29 Million ≈ $9.26 Million |
CN¥4.83 Billion ≈ $706.71 Million |
-12.02pp |
| 2022-12-31 | 13.33% | CN¥674.35 Million ≈ $98.68 Million |
CN¥5.06 Billion ≈ $740.09 Million |
+10.76pp |
| 2021-12-31 | 2.57% | CN¥106.02 Million ≈ $15.51 Million |
CN¥4.13 Billion ≈ $603.90 Million |
+1.63pp |
| 2020-12-31 | 0.94% | CN¥36.32 Million ≈ $5.31 Million |
CN¥3.87 Billion ≈ $565.78 Million |
-1.93pp |
| 2019-12-31 | 2.87% | CN¥94.32 Million ≈ $13.80 Million |
CN¥3.29 Billion ≈ $480.76 Million |
+0.11pp |
| 2018-12-31 | 2.77% | CN¥80.93 Million ≈ $11.84 Million |
CN¥2.93 Billion ≈ $428.24 Million |
-4.79pp |
| 2017-12-31 | 7.55% | CN¥208.00 Million ≈ $30.44 Million |
CN¥2.75 Billion ≈ $402.99 Million |
+6.71pp |
| 2016-12-31 | 0.85% | CN¥21.17 Million ≈ $3.10 Million |
CN¥2.50 Billion ≈ $365.35 Million |
-0.35pp |
| 2015-12-31 | 1.20% | CN¥28.81 Million ≈ $4.22 Million |
CN¥2.41 Billion ≈ $352.64 Million |
-1.19pp |
| 2014-12-31 | 2.38% | CN¥52.05 Million ≈ $7.62 Million |
CN¥2.19 Billion ≈ $319.83 Million |
+0.41pp |
| 2013-12-31 | 1.97% | CN¥39.98 Million ≈ $5.85 Million |
CN¥2.03 Billion ≈ $296.68 Million |
-0.06pp |
| 2012-12-31 | 2.03% | CN¥37.37 Million ≈ $5.47 Million |
CN¥1.84 Billion ≈ $269.67 Million |
-3.47pp |
| 2011-12-31 | 5.49% | CN¥91.07 Million ≈ $13.33 Million |
CN¥1.66 Billion ≈ $242.56 Million |
+1.34pp |
| 2010-12-31 | 4.15% | CN¥60.12 Million ≈ $8.80 Million |
CN¥1.45 Billion ≈ $212.02 Million |
+1.42pp |
| 2009-12-31 | 2.73% | CN¥39.15 Million ≈ $5.73 Million |
CN¥1.44 Billion ≈ $210.11 Million |
-10.32pp |
| 2008-12-31 | 13.05% | CN¥151.74 Million ≈ $22.20 Million |
CN¥1.16 Billion ≈ $170.17 Million |
+9.31pp |
| 2007-12-31 | 3.74% | CN¥40.84 Million ≈ $5.98 Million |
CN¥1.09 Billion ≈ $159.74 Million |
+3.61pp |
| 2006-12-31 | 0.13% | CN¥1.45 Million ≈ $211.62K |
CN¥1.11 Billion ≈ $161.80 Million |
+0.12pp |
| 2003-12-31 | 0.01% | CN¥50.59K ≈ $7.40K |
CN¥367.95 Million ≈ $53.84 Million |
-0.15pp |
| 2002-12-31 | 0.16% | CN¥580.07K ≈ $84.88K |
CN¥363.13 Million ≈ $53.14 Million |
+0.11pp |
| 2001-12-31 | 0.05% | CN¥151.42K ≈ $22.16K |
CN¥320.89 Million ≈ $46.96 Million |
-- |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers… Read more